Yangzijiang Financial (YF8) stock ticks up in Singapore as U.S. CPI and Fed tensions loom
12 January 2026
1 min read

Yangzijiang Financial (YF8) stock ticks up in Singapore as U.S. CPI and Fed tensions loom

SINGAPORE, Jan 12, 2026, 15:41 SGT — Regular session

Shares of Yangzijiang Financial Holding Ltd nudged up 1.3% to S$0.38 Monday afternoon, clawing back part of their early-January losses. The Singapore-listed investment firm hasn’t posted any new updates on SGXNet since November 17, according to exchange filings. 1

Investors reacted sharply after Federal Reserve Chair Jerome Powell revealed that the Trump administration had threatened him with a criminal indictment and issued subpoenas, raising fresh doubts about the Fed’s independence. “Trump is pulling at the loose threads of central bank independence,” said Andrew Lilley, chief rates strategist at Barrenjoey. The news sent gold soaring to record highs while the dollar weakened. 2

Why this matters for Yangzijiang Financial: the company handles investment management, fund and wealth management, and also holds stakes in debt instruments and other assets, according to SGX corporate data. Such a portfolio can be volatile, reacting to credit market shifts and mark-to-market adjustments—meaning it values holdings at current prices—as interest rates and risk appetite fluctuate. 3

Singapore’s Straits Times Index climbed roughly 0.6% by mid-afternoon, holding firmer ground compared to several overseas markets. 4

Trading activity remained strong, with roughly 24.3 million shares changing hands on Monday. This figure tracks closely with recent volumes, according to exchange data from 8 .

Flows worked against Yangzijiang Financial. In the first five trading days of 2026, it was one of the stocks with the largest net institutional outflows, despite institutions buying Singapore shares overall, SGX market strategist Geoff Howie noted in The Business Times. 5

According to consensus estimates tracked by Beansprout, Yangzijiang Financial’s target price stood at 47.2 Singapore cents as of Jan. 12, suggesting potential gains from current levels. The compilation also included an “add” rating from CGS-CIMB. 6

The setup remains delicate. Should U.S. inflation stay elevated and expectations for rate cuts fade, risk assets could repric e swiftly — a scenario that often squeezes investment portfolios and widens financing spreads, potentially denting fee income if markets falter.

Investors are zeroing in on the U.S. consumer price index for December, set for release Tuesday, Jan. 13, at 8:30 a.m. Eastern. This key figure frequently shifts global rate forecasts and tends to influence trading across Asia. 7

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
iFAST stock edges up in Singapore as investors size up Feb 12 results, Financial Alliance deal
Previous Story

iFAST stock edges up in Singapore as investors size up Feb 12 results, Financial Alliance deal

Lemon Tree Hotels stock jumps on Warburg Pincus-backed Fleur split as brokerages flag upside
Next Story

Lemon Tree Hotels stock jumps on Warburg Pincus-backed Fleur split as brokerages flag upside

Go toTop